Extensively drug-resistant tuberculosis: A sign of the times and an impetus for antimicrobial discovery

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

Mycobacterium tuberculosis is an extraordinarily successful human pathogen, infecting one-third of the world's population and causing nearly two million deaths each year. In this article, current trends in worldwide tuberculosis (TB) incidence, prevalence, and mortality are discussed along with standard TB treatment regimens, characteristics of first-line and second-line anti-tuberculosis drugs, and mechanisms of antibiotic resistance. The global TB emergency has been further exacerbated by extensively drug-resistant (XDR) TB strains that are resistant to our best antibiotics and very difficult to treat. This review also focuses on the emergence of XDR-TB strains, the global health impact, and existing treatment options and outcomes for XDR-TB disease. Finally, this review briefly describes new antituberculosis drugs currently in Phase II clinical evaluations and the impetus for discovering new antibacterial compounds to target drug-resistant M. tuberculosis and improve tuberculosis therapy.

Original languageEnglish (US)
Pages (from-to)2268-2290
Number of pages23
JournalPharmaceuticals
Volume3
Issue number7
DOIs
StatePublished - Aug 24 2010

    Fingerprint

Keywords

  • Antimicrobial
  • Drug
  • Resistance
  • Tuberculosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this